Source - SMW
NetScientific's portfolio company Glycotest has been granted a Chinese patent providing broad protection of the assays in Glycotest's HCC Panel test for early-stage hepatocellular carcinoma (HCC) and pipeline tests for liver fibrosis and other serious liver disease.

This patent expands Glycotest's existing patent portfolio which has 10 previously granted or allowed patents, protecting multiple aspects of Glycotest's proprietary liver disease diagnostic platform.

Glycotest now holds patents in the US, Europe, Japan and Australia covering the use of over 50 unique glycoprotein biomarkers and related assay technology for the diagnosis of liver cancers and other liver diseases.

These patents have been licensed exclusively on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation. 

Glycotest's lead product, HCC Panel, has demonstrated in two studies of 208 patients and 127 patients respectively that it has the potential to outperform the current dominant blood test (AFP) regarding the early detection of HCC in patients with cirrhosis.

NetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest.   


At 9:21am: (LON:NSCI) Netscientific Plc share price was 0p at 54.5p



Related Charts

Netscientific (NSCI)

0.00 (0.00%)
delayed 16:55PM